Gastroenterology
Volume 136, Issue 2 , Pages 425-440 , February 2009

Roles of Infection, Inflammation, and the Immune System in Cholesterol Gallstone Formation

  • Kirk J. Maurer

      Affiliations

    • Division of Gastroenterology, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts
    • Corresponding Author InformationAddress requests for reprints to: Kirk J. Maurer, DVM, PhD, Cornell Center for Animal Resources and Education, College of Veterinary Medicine, Cornell University, Ithaca, New York. fax: (607) 253-3527
    • ,
  • Martin C. Carey

      Affiliations

    • Division of Gastroenterology, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • ,
  • James G. Fox

      Affiliations

    • Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts
    • Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts

Received 16 July 2008 ,Accepted 8 December 2008.

References 

  1. Carey MC, Lamont JT. Cholesterol gallstone formation (1. Physical-chemistry of bile and biliary lipid secretion). Prog Liver Dis. 1992;10:139–163
  2. Carey MC. Pathogenesis of gallstones. Am J Surg. 1993;165:410–419
  3. Paigen B, Carey MC. Gallstones. In:  King RA,  Rotter JI,  Motulsky AG editor. Genetic basis of common diseases. 2nd ed.. New York, NY: Oxford University Press; 2002;p. 298–335
  4. Carey MC. Pathogenesis of gallstones. Recenti Prog Med. 1992;83:379–391
  5. Lee SP, LaMont JT, Carey MC. Role of gallbladder mucus hypersecretion in the evolution of cholesterol gallstones. J Clin Invest. 1981;67:1712–1723
  6. Wang DQ, Paigen B, Carey MC. Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: physical-chemistry of gallbladder bile. J Lipid Res. 1997;38:1395–1411
  7. Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology. 2001;120:1459–1467
  8. Carey MC, Cahalane MJ. Whither biliary sludge?. Gastroenterology. 1988;95:508–523
  9. Lee SP, Hayashi A, Kim YS. Biliary sludge: curiosity or culprit?. Hepatology. 1994;20:523–525
  10. Lee SP, Maher K, Nicholls JF. Origin and fate of biliary sludge. Gastroenterology. 1988;94:170–176
  11. Lammert F, Matern S. The genetic background of cholesterol gallstone formation: an inventory of human lithogenic genes. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5:163–170
  12. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368:230–239
  13. van Erpecum KJ. Biliary lipids, water and cholesterol gallstones. Biol Cell. 2005;97:815–822
  14. Wang DQ, Afdhal NH. Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. Curr Gastroenterol Rep. 2004;6:140–150
  15. Katsika D, Grjibovski A, Einarsson C, et al. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology. 2005;41:1138–1143
  16. Maurer KJ, Ihrig MM, Rogers AB, et al. Identification of cholelithogenic enterohepatic helicobacter species and their role in murine cholesterol gallstone formation. Gastroenterology. 2005;128:1023–1033
  17. Maurer KJ, Rogers AB, Ge Z, et al. Helicobacter pylori and cholesterol gallstone formation in C57L/J mice: a prospective study. Am J Physiol Gastrointest Liver Physiol. 2006;290:G175–G182
  18. Maurer KJ, Rao VP, Ge Z, et al. T-cell function is critical for murine cholesterol gallstone formation. Gastroenterology. 2007;133:1304–1315
  19. Rege RV, Prystowsky JB. Inflammation and a thickened mucus layer in mice with cholesterol gallstones. J Surg Res. 1998;74:81–85
  20. Baig SJ, Biswas S, Das S, et al. Histopathological changes in gallbladder mucosa in cholelithiasis: correlation with chemical composition of gallstones. Trop Gastroenterol. 2002;23:25–27
  21. Hofmann AF. Pathogenesis of cholesterol gallstones. J Clin Gastroenterol. 1988;10(Suppl 2):S1–S11
  22. van Erpecum KJ, Wang DQ, Lammert F, et al. Phenotypic characterization of Lith genes that determine susceptibility to cholesterol cholelithiasis in inbred mice: soluble pronucleating proteins in gallbladder and hepatic biles. J Hepatol. 2001;35:444–451
  23. van Erpecum KJ, Wang DQ, Moschetta A, et al. Gallbladder histopathology during murine gallstone formation: relation to motility and concentrating function. J Lipid Res. 2006;47:32–41
  24. Strasberg SM, Harvey PR. Biliary cholesterol transport and precipitation: introduction and overview of conference. Hepatology. 1990;12:1S–5S
  25. Auth MK, Keitzer RA, Scholz M, et al. Establishment and immunological characterization of cultured human gallbladder epithelial cells. Hepatology. 1993;18:546–555
  26. Rumin S, Loreal O, Drenou B, et al. Patterns of intermediate filaments, VLA integrins and HLA antigens in a new human biliary epithelial cell line sensitive to interferon-gamma. J Hepatol. 1997;26:1287–1299
  27. Harada K, Ohba K, Ozaki S, et al. Peptide antibiotic human beta-defensin-1 and -2 contribute to antimicrobial defense of the intrahepatic biliary tree. Hepatology. 2004;40:925–932
  28. Harada K, Ohira S, Isse K, et al. Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells. Lab Invest. 2003;83:1657–1667
  29. Reynoso-Paz S, Coppel RL, Mackay IR, et al. The immunobiology of bile and biliary epithelium. Hepatology. 1999;30:351–357
  30. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801
  31. Fritz JH, Girardin SE. How Toll-like receptors and Nod-like receptors contribute to innate immunity in mammals. J Endotoxin Res. 2005;11:390–394
  32. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006;124:823–835
  33. Banyer JL, Hamilton NH, Ramshaw IA, et al. Cytokines in innate and adaptive immunity. Rev Immunogenet. 2000;2:359–373
  34. Fagarasan S. Intestinal IgA synthesis: a primitive form of adaptive immunity that regulates microbial communities in the gut. Curr Top Microbiol Immunol. 2006;308:137–153
  35. Firestein GS. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest. 2004;114:471–474
  36. Flajnik MF, Du Pasquier L. Evolution of innate and adaptive immunity: can we draw a line?. Trends Immunol. 2004;25:640–644
  37. Harada K, Isse K, Sato Y, et al. Endotoxin tolerance in human intrahepatic biliary epithelial cells is induced by upregulation of IRAK-M. Liver Int. 2006;26:935–942
  38. Chen XM, O'Hara SP, Nelson JB, et al. Multiple TLRs are expressed in human cholangiocytes and mediate host epithelial defense responses to Cryptosporidium parvum via activation of NF-kappaB. J Immunol. 2005;175:7447–7456
  39. Rogers KA, Rogers AB, Leav BA, et al. MyD88-dependent pathways mediate resistance to Cryptosporidium parvum infection in mice. Infect Immun. 2006;74:549–556
  40. Aoki CA, Bowlus CL, Gershwin ME. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev. 2005;4:137–143
  41. Adams DH, Afford SC. The role of cholangiocytes in the development of chronic inflammatory liver disease. Front Biosci. 2002;7:e276–e285
  42. Adams DH, Afford SC. Effector mechanisms of nonsuppurative destructive cholangitis in graft-versus-host disease and allograft rejection. Semin Liver Dis. 2005;25:281–297
  43. Bloom S, Fleming K, Chapman R. Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut. 1995;36:604–609
  44. Howell CD, Li J, Chen W. Role of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 during nonsuppurative destructive cholangitis in a mouse graft-versus-host disease model. Hepatology. 1999;29:766–776
  45. Korlipara LV, Leon MP, Rix DA, et al. Development of a flow cytometric assay to quantify lymphocyte adhesion to cytokine-stimulated human endothelial and biliary epithelial cells. J Immunol Methods. 1996;191:121–130
  46. Kaetzel CS. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev. 2005;206:83–99
  47. Mostov KE. Transepithelial transport of immunoglobulins. Annu Rev Immunol. 1994;12:63–84
  48. Norderhaug IN, Johansen FE, Schjerven H, et al. Regulation of the formation and external transport of secretory immunoglobulins. Crit Rev Immunol. 1999;19:481–508
  49. Rojas R, Apodaca G. Immunoglobulin transport across polarized epithelial cells. Nat Rev Mol Cell Biol. 2002;3:944–955
  50. Dickinson BL, Claypool SM, D'Angelo JA, et al. Ca2+-dependent calmodulin binding to FcRn affects immunoglobulin G transport in the transcytotic pathway. Mol Biol Cell. 2008;19:414–423
  51. Blumberg RS, Koss T, Story CM, et al. A major histocompatibility complex class I-related Fc receptor for IgG on rat hepatocytes. J Clin Invest. 1995;95:2397–2402
  52. Brown WR, Kloppel TM. The liver and IgA: immunological, cell biological and clinical implications. Hepatology. 1989;9:763–784
  53. McQueen CE, Boedeker EC, Le M, et al. Mucosal immune response to RDEC-1 infection: study of lamina propria antibody-producing cells and biliary antibody. Infect Immun. 1992;60:206–212
  54. Savard CE, Blinman TA, Choi HS, et al. Expression of cytokine and chemokine mRNA and secretion of tumor necrosis factor-alpha by gallbladder epithelial cells: response to bacterial lipopolysaccharides. BMC Gastroenterol. 2002;2:23
  55. Shi JS, Zhou LS, Han Y, et al. Expression of tumor necrosis factor and its receptor in gallstone and gallbladder carcinoma tissue. Hepatobiliary Pancreat Dis Int. 2004;3:448–452
  56. Rege RV. Inflammatory cytokines alter human gallbladder epithelial cell absorption/secretion. J Gastrointest Surg. 2000;4:185–192
  57. Prystowsky JB, Rege RV. Interleukin-1 mediates guinea pig gallbladder inflammation in vivo. J Surg Res. 1997;71:123–126
  58. Chung-Park M, Kim B, Marmolya G, et al. Acalculus lymphoeosinophilic cholecystitis associated with interleukin-2 and lymphokine-activated killer cell therapy. Arch Pathol Lab Med. 1990;114:1073–1075
  59. Dickey KW, Barth RA, Stewart JA. Recurrent transient gallbladder wall thickening associated with interleukin-2 chemotherapy. J Clin Ultrasound. 1993;21:58–61
  60. Powell FC, Spooner KM, Shawker TH, et al. Symptomatic interleukin-2-induced cholecystopathy in patients with HIV infection. AJR Am J Roentgenol. 1994;163:117–121
  61. Mori M, Miyazaki K. Factors affecting morphogenesis of rabbit gallbladder epithelial cells cultured in collagen gels. Cell Tissue Res. 2000;300:331–344
  62. Koninger J, di Mola FF, Di Sebastiano P, et al. Transforming growth factor-beta pathway is activated in cholecystolithiasis. Langenbecks Arch Surg. 2005;390:21–28
  63. Hemming JM, Guarraci FA, Firth TA, et al. Actions of histamine on muscle and ganglia of the guinea pig gallbladder. Am J Physiol Gastrointest Liver Physiol. 2000;279:G622–G630
  64. He XS, Ansari AA, Ridgway WM, et al. New insights to the immunopathology and autoimmune responses in primary biliary cirrhosis. Cell Immunol. 2006;239:1–13
  65. Alba LM, Angulo P, Lindor KD. Primary sclerosing cholangitis. Minerva Gastroenterol Dietol. 2002;48:99–113
  66. Cullen S, Chapman R. Primary sclerosing cholangitis. Autoimmun Rev. 2003;2:305–312
  67. Koukoulis GK, Shen J, Karademir S, et al. Cholangiocytic apoptosis in chronic ductopenic rejection. Hum Pathol. 2001;32:823–827
  68. Harvey PR, Upadhya GA, Strasberg SM. Immunoglobulins as nucleating proteins in the gallbladder bile of patients with cholesterol gallstones. J Biol Chem. 1991;266:13996–14003
  69. Harvey PR, Upadhya GA. A rapid, simple high capacity cholesterol crystal growth assay. J Lipid Res. 1995;36:2054–2058
  70. Upadhya GA, Harvey PR, Strasberg SM. Effect of human biliary immunoglobulins on the nucleation of cholesterol. J Biol Chem. 1993;268:5193–5200
  71. Paigen B, Schork NJ, Svenson KL, et al. Quantitative trait loci mapping for cholesterol gallstones in AKR/J and C57L/J strains of mice. Physiol Genomics. 2000;4:59–65
  72. Miquel JF, Nunez L, Amigo L, et al. Cholesterol saturation, not proteins or cholecystitis, is critical for crystal formation in human gallbladder bile. Gastroenterology. 1998;114:1016–1023
  73. Lipsett PA, Hildreth J, Kaufman HS, et al. Human gallstones contain pronucleating nonmucin glycoproteins that are immunoglobulins. Ann Surg. 1994;219:25–33
  74. Andrianifahanana M, Moniaux N, Batra SK. Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta. 2006;1765:189–222
  75. Lammert F, Wang DQ, Wittenburg H, et al. Lith genes control mucin accumulation, cholesterol crystallization, and gallstone formation in A/J and AKR/J inbred mice. Hepatology. 2002;36:1145–1154
  76. LaMont JT, Smith BF, Moore JR. Role of gallbladder mucin in pathophysiology of gallstones. Hepatology. 1984;4:51S–56S
  77. Lee KT, Liu TS. Mucin gene expression in gallbladder epithelium. J Formos Med Assoc. 2002;101:762–768
  78. Wang HH, Afdhal NH, Gendler SJ, et al. Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation. J Lipid Res. 2004;45:438–447
  79. Wang HH, Afdhal NH, Gendler SJ, et al. Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice. Gastroenterology. 2006;131:210–222
  80. Afdhal NH, Niu N, Gantz D, et al. Bovine gallbladder mucin accelerates cholesterol monohydrate crystal growth in model bile. Gastroenterology. 1993;104:1515–1523
  81. Levy PF, Smith BF, LaMont JT. Human gallbladder mucin accelerates nucleation of cholesterol in artificial bile. Gastroenterology. 1984;87:270–275
  82. Smith BF. Gallbladder mucin as a pronucleating agent for cholesterol monohydrate crystals in bile. Hepatology. 1990;12:183S–186Sdiscussion 186S–188S
  83. Yamasaki T, Chijiiwa K, Endo M. Isolation of mucin from human hepatic bile and its induced effects on precipitation of cholesterol and calcium carbonate in vitro. Dig Dis Sci. 1993;38:909–915
  84. Zen Y, Harada K, Sasaki M, et al. Lipopolysaccharide induces overexpression of MUC2 and MUC5AC in cultured biliary epithelial cells: possible key phenomenon of hepatolithiasis. Am J Pathol. 2002;161:1475–1484
  85. Ikeda H, Sasaki M, Ishikawa A, et al. Interaction of Toll-like receptors with bacterial components induces expression of CDX2 and MUC2 in rat biliary epithelium in vivo and in culture. Lab Invest. 2007;87:559–571
  86. Sakamoto H, Mutoh H, Ido K, et al. A close relationship between intestinal metaplasia and Cdx2 expression in human gallbladders with cholelithiasis. Hum Pathol. 2007;38:66–71
  87. Choi J, Klinkspoor JH, Yoshida T, et al. Lipopolysaccharide from Escherichia coli stimulates mucin secretion by cultured dog gallbladder epithelial cells. Hepatology. 1999;29:1352–1357
  88. Finzi L, Barbu V, Burgel PR, et al. MUC5AC, a gel-forming mucin accumulating in gallstone disease, is overproduced via an epidermal growth factor receptor pathway in the human gallbladder. Am J Pathol. 2006;169:2031–2041
  89. Little TE, Madani H, Lee SP, et al. Lipid vesicle fusion induced by phospholipase C activity in model bile. J Lipid Res. 1993;34:211–217
  90. Offner GD, Gong D, Afdhal NH. Identification of a 130-kilodalton human biliary concanavalin A binding protein as aminopeptidase N. Gastroenterology. 1994;106:755–762
  91. Zhou H, Chen B, Li RX, et al. Large-scale identification of human biliary proteins from a cholesterol stone patient using a proteomic approach. Rapid Commun Mass Spectrom. 2005;19:3569–3578
  92. Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med. 2004;10:1352–1358
  93. Lyons MA, Wittenburg H. Susceptibility to cholesterol gallstone formation: Evidence that LITH genes also encode immune-related factors. Biochim Biophys Acta. 2006;1761:1133–1147
  94. Portincasa P, Di Ciaula A, Vendemiale G, et al. Gallbladder motility and cholesterol crystallization in bile from patients with pigment and cholesterol gallstones. Eur J Clin Invest. 2000;30:317–324
  95. Lee SP. Lessons from experimental cholelithiasis: gallbladder and mucosa, nonsteroidal antiinflammatory drugs, and gallstones. Gastroenterology. 1991;101:857–860
  96. Xiao ZL, Amaral J, Biancani P, et al. Impaired cytoprotective function of muscle in human gallbladders with cholesterol stones. Am J Physiol Gastrointest Liver Physiol. 2005;288:G525–G532
  97. van de Heijning BJ, van de Meeberg PC, Portincasa P, et al. Effects of ursodeoxycholic acid therapy on in vitro gallbladder contractility in patients with cholesterol gallstones. Dig Dis Sci. 1999;44:190–196
  98. Haigh WG, Lee SP. Identification of oxysterols in human bile and pigment gallstones. Gastroenterology. 2001;121:118–123
  99. Seo DW, Choi HS, Lee SP, et al. Oxysterols from human bile induce apoptosis of canine gallbladder epithelial cells in monolayer culture. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1247–G1256
  100. Lee SP, Carey MC, LaMont JT. Aspirin prevention of cholesterol gallstone formation in prairie dogs. Science. 1981;211:1429–1431
  101. Adamek HE, Buttmann A, Weber J, et al. Can aspirin prevent gallstone recurrence after successful extracorporeal shockwave lithotripsy?. Scand J Gastroenterol. 1994;29:355–359
  102. Broomfield PH, Chopra R, Sheinbaum RC, et al. Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight. N Engl J Med. 1988;319:1567–1572
  103. Cohen BI, Mosbach EH, Ayyad N, et al. Aspirin does not inhibit cholesterol cholelithiasis in two established animal models. Gastroenterology. 1991;101:1109–1116
  104. Kurata JH, Marks J, Abbey D. One gram of aspirin per day does not reduce risk of hospitalization for gallstone disease. Dig Dis Sci. 1991;36:1110–1115
  105. Li YF, Russell DH, Myers SI, et al. Gallbladder contractility in aspirin- and cholesterol-fed prairie dogs. Gastroenterology. 1994;106:1662–1667
  106. Araki Y, Andoh A, Bamba H, et al. The cytotoxicity of hydrophobic bile acids is ameliorated by more hydrophilic bile acids in intestinal cell lines IEC-6 and Caco-2. Oncol Rep. 2003;10:1931–1936
  107. Yui S, Saeki T, Kanamoto R, et al. Characteristics of apoptosis in HCT116 colon cancer cells induced by deoxycholic acid. J Biochem (Tokyo). 2005;138:151–157
  108. Lamireau T, Zoltowska M, Levy E, et al. Effects of bile acids on biliary epithelial cells: proliferation, cytotoxicity, and cytokine secretion. Life Sci. 2003;72:1401–1411
  109. Kano M, Shoda J, Irimura T, et al. Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones. Hepatology. 1998;28:302–313
  110. Maurer KJ. A systematic evaluation of the role of infection, immunity and inflammation in cholesterol gallstone pathogenesis. [doctoral thesis] Cambridge, MA: Massachusetts Institute of Technology; 2007;159
  111. Paumgartner G, Pauletzki J, Sackmann M. Ursodeoxycholic acid treatment of cholesterol gallstone disease. Scand J Gastroenterol Suppl. 1994;204:27–31
  112. Paumgartner G, Sauerbruch T. Gallstones: pathogenesis. Lancet. 1991;338:1117–1121
  113. Henkel A, Wei Z, Cohen DE, et al. Mice overexpressing hepatic Abcb11 rapidly develop cholesterol gallstones. Mamm Genome. 2005;16:903–908
  114. Portincasa P, van de Meeberg P, van Erpecum KJ, et al. An update on the pathogenesis and treatment of cholesterol gallstones. Scand J Gastroenterol Suppl. 1997;223:60–69
  115. Merselis JG, Kaye D, Connolly CS, et al. The typhoid carrier state: quantitative bacteriology and preliminary observations on therapy. East Afr Med J. 1964;41:219–227
  116. Rains AJ, Barson GJ, Crawford N, et al. A chemical and bacteriological study of gallstones (The presence of an actinomycete). Lancet. 1960;2:614–618
  117. Scott AJ, Khan GA. Origin of bacteria in bileduct bile. Lancet. 1967;2:790–792
  118. Salen G. Gallstone dissolution therapy with ursodiol (Efficacy and safety). Dig Dis Sci. 1989;34:39S–43S
  119. Hellstern A, Leuschner U, Benjaminov A, et al. Dissolution of gallbladder stones with methyl tert-butyl ether and stone recurrence: a European survey. Dig Dis Sci. 1998;43:911–920
  120. Pauletzki J, Holl J, Sackmann M, et al. Gallstone recurrence after direct contact dissolution with methyl tert-butyl ether. Dig Dis Sci. 1995;40:1775–1781
  121. Lamont JT, Carey MC. Cholesterol gallstone formation (2. Pathobiology and pathomechanics). Prog Liver Dis. 1992;10:165–191
  122. Cahalane MJ, Neubrand MW, Carey MC. Physical-chemical pathogenesis of pigment gallstones. Semin Liver Dis. 1988;8:317–328
  123. Lee DK, Tarr PI, Haigh WG, et al. Bacterial DNA in mixed cholesterol gallstones. Am J Gastroenterol. 1999;94:3502–3506
  124. Swidsinski A, Lee SP. The role of bacteria in gallstone pathogenesis. Front Biosci. 2001;6:E93–E103
  125. Swidsinski A, Ludwig W, Pahlig H, et al. Molecular genetic evidence of bacterial colonization of cholesterol gallstones. Gastroenterology. 1995;108:860–864
  126. Wu XT, Xiao LJ, Li XQ, et al. Detection of bacterial DNA from cholesterol gallstones by nested primers polymerase chain reaction. World J Gastroenterol. 1998;4:234–237
  127. Kawai M, Iwahashi M, Uchiyama K, et al. Gram-positive cocci are associated with the formation of completely pure cholesterol stones. Am J Gastroenterol. 2002;97:83–88
  128. Vitetta L, Sali A, Moritz V, et al. Bacteria and gallstone nucleation. Aust N Z J Surg. 1989;59:571–577
  129. Vitetta L, Best SP, Sali A. Single and multiple cholesterol gallstones and the influence of bacteria. Med Hypotheses. 2000;55:502–506
  130. Whiting MJ, Watts JM. Cholesterol gallstone pathogenesis: a study of potential nucleating agents for cholesterol crystal formation in bile. Clin Sci (Lond). 1985;68:589–596
  131. Farshad S, Alborzi A, Malek Hosseini SA, et al. Identification of Helicobacter pylori DNA in Iranian patients with gallstones. Epidemiol Infect. 2004;132:1185–1189
  132. Monstein HJ, Jonsson Y, Zdolsek J, et al. Identification of Helicobacter pylori DNA in human cholesterol gallstones. Scand J Gastroenterol. 2002;37:112–119
  133. Myung SJ, Kim MH, Shim KN, et al. Detection of Helicobacter pylori DNA in human biliary tree and its association with hepatolithiasis. Dig Dis Sci. 2000;45:1405–1412
  134. Silva CP, Pereira-Lima JC, Oliveira AG, et al. Association of the presence of Helicobacter in gallbladder tissue with cholelithiasis and cholecystitis. J Clin Microbiol. 2003;41:5615–5618
  135. Mathai E, Arora A, Cafferkey M, et al. The effect of bile acids on the growth and adherence of Helicobacter pylori. Aliment Pharmacol Ther. 1991;5:653–658
  136. Worku ML, Karim QN, Spencer J, et al. Chemotactic response of Helicobacter pylori to human plasma and bile. J Med Microbiol. 2004;53:807–811
  137. Kawaguchi M, Saito T, Ohno H, et al. Bacteria closely resembling Helicobacter pylori detected immunohistologically and genetically in resected gallbladder mucosa. J Gastroenterol. 1996;31:294–298
  138. O'Rourke JL, Solnick JV, Neilan BA, et al. Description of ‘Candidatus Helicobacter heilmannii’ based on DNA sequence analysis of 16S rRNA and urease genes. Int J Syst Evol Microbiol. 2004;54:2203–2211
  139. Avenaud P, Marais A, Monteiro L, et al. Detection of Helicobacter species in the liver of patients with and without primary liver carcinoma. Cancer. 2000;89:1431–1439
  140. Fox J. Enterohepatic Helicobacters: natural and experimental models. Ital J Gastroenterol Hepatol. 1998;30(Suppl 3):S264–S269
  141. Solnick JV, Schauer DB. Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev. 2001;14:59–97
  142. Fox JG, Dewhirst FE, Shen Z, et al. Hepatic Helicobacter species identified in bile and gallbladder tissue from Chileans with chronic cholecystitis. Gastroenterology. 1998;114:755–763
  143. Matsukura N, Yokomuro S, Yamada S, et al. Association between Helicobacter bilis in bile and biliary tract malignancies: H. bilis in bile from Japanese and Thai patients with benign and malignant diseases in the biliary tract. Jpn J Cancer Res. 2002;93:842–847
  144. Belzer C, Kusters JG, Kuipers EJ, et al. Urease induced calcium precipitation by Helicobacter species may initiate gallstone formation. Gut. 2006;55:1678–1679
  145. Sanabria JR, Upadhya GA, Harvey RP, et al. Diffusion of substances into human cholesterol gallstones. Gastroenterology. 1994;106:749–754
  146. Bruce IJ. Nucleic acid amplification mediated microbial identification. Sci Prog. 1993;77:183–206
  147. Davis RE, Jomantiene R, Kalvelyte A, et al. Differential amplification of sequence heterogeneous ribosomal RNA genes and classification of the ‘Fragaria multicipita’ phytoplasma. Microbiol Res. 2003;158:229–236
  148. King S, McCord BR, Riefler RG. Capillary electrophoresis single-strand conformation polymorphism analysis for monitoring soil bacteria. J Microbiol Methods. 2005;60:83–92
  149. Dutta U, Garg PK, Kumar R, et al. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol. 2000;95:784–787
  150. Lai CW, Chan RC, Cheng AF, et al. Common bile duct stones: a cause of chronic salmonellosis. Am J Gastroenterol. 1992;87:1198–1199
  151. Prouty AM, Schwesinger WH, Gunn JS. Biofilm formation and interaction with the surfaces of gallstones by Salmonella spp. Infect Immun. 2002;70:2640–2649
  152. Prouty AM, Gunn JS. Comparative analysis of Salmonella enterica serovar Typhimurium biofilm formation on gallstones and on glass. Infect Immun. 2003;71:7154–7158
  153. Bini EJ, McGready J. Prevalence of gallbladder disease among persons with hepatitis C virus infection in the United States. Hepatology. 2005;41:1029–1036
  154. Chang TS, Lo SK, Shyr HY, et al. Hepatitis C virus infection facilitates gallstone formation. J Gastroenterol Hepatol. 2005;20:1416–1421
  155. Elzouki AN, Nilsson S, Nilsson P, et al. The prevalence of gallstones in chronic liver disease is related to degree of liver dysfunction. Hepatogastroenterology. 1999;46:2946–2950
  156. Sheen IS, Liaw YF. The prevalence and incidence of cholecystolithiasis in patients with chronic liver diseases: a prospective study. Hepatology. 1989;9:538–540
  157. Loriot MA, Bronowicki JP, Lagorce D, et al. Permissiveness of human biliary epithelial cells to infection by hepatitis C virus. Hepatology. 1999;29:1587–1595
  158. Nouri Aria KT, Sallie R, Sangar D, et al. Detection of genomic and intermediate replicative strands of hepatitis C virus in liver tissue by in situ hybridization. J Clin Invest. 1993;91:2226–2234
  159. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003;36:417–420
  160. Fraquelli M, Losco A, Visentin S, et al. Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. Arch Intern Med. 2001;161:2201–2204
  161. Kratzer W, Haenle MM, Mason RA, et al. Prevalence of cholelithiasis in patients with chronic inflammatory bowel disease. World J Gastroenterol. 2005;11:6170–6175
  162. Whorwell PJ, Hawkins R, Dewbury K, et al. Ultrasound survey of gallstones and other hepatobiliary disorders in patients with Crohn's disease. Dig Dis Sci. 1984;29:930–933
  163. Hutchinson R, Tyrrell PN, Kumar D, et al. Pathogenesis of gall stones in Crohn's disease: an alternative explanation. Gut. 1994;35:94–97
  164. Pereira SP, Bain IM, Kumar D, et al. Bile composition in inflammatory bowel disease: ileal disease and colectomy, but not colitis, induce lithogenic bile. Aliment Pharmacol Ther. 2003;17:923–933
  165. Freudenberg F, Carey MC. Hepatobiliary manifestations in inflammatory bowel disease. In:  Blumberg RS,  Gangl A,  Manns MP editor. Gut-Liver Interactions: Basic and Clinical Concepts. Dordrecht, The Netherlands: Springer; 2005;p. 165–176
  166. Lapidus A, Einarsson C. Bile composition in patients with ileal resection due to Crohn's disease. Inflamm Bowel Dis. 1998;4:89–94
  167. Lapidus A, Einarsson K. Effects of ileal resection on biliary lipids and bile acid composition in patients with Crohn's disease. Gut. 1991;32:1488–1491
  168. Hofmann AF. Medical dissolution of gallstones by oral bile acid therapy. Am J Surg. 1989;158:198–204
  169. Jungst D, Brenner G, Pratschke E, et al. Low-dose ursodeoxycholic acid prolongs cholesterol nucleation time in gallbladder bile of patients with cholesterol gallstones. J Hepatol. 1989;8:1–6
  170. Bamias G, Sugawara K, Pagnini C, et al. The Th1 immune pathway as a therapeutic target in Crohn's disease. Curr Opin Investig Drugs. 2003;4:1279–1286
  171. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550–564
  172. Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 2002;17:629–638
  173. Feingold KR, Pollock AS, Moser AH, et al. Discordant regulation of proteins of cholesterol metabolism during the acute phase response. J Lipid Res. 1995;36:1474–1482
  174. Hardardottir I, Grunfeld C, Feingold KR. Effects of endotoxin on lipid metabolism. Biochem Soc Trans. 1995;23:1013–1018
  175. Hardardottir I, Moser AH, Memon R, et al. Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. Lymphokine Cytokine Res. 1994;13:161–166
  176. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45:1169–1196
  177. Memon RA, Shechter I, Moser AH, et al. Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters. J Lipid Res. 1997;38:1620–1629
  178. Feingold KR, Hardardottir I, Memon R, et al. Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. J Lipid Res. 1993;34:2147–2158
  179. Yoo JY, Desiderio S. Innate and acquired immunity intersect in a global view of the acute-phase response. Proc Natl Acad Sci U S A. 2003;100:1157–1162
  180. Mookerjea S, Coolbear T, Sarkar ML. Key role of dolichol phosphate in glycoprotein biosynthesis. Can J Biochem Cell Biol. 1983;61:1032–1040
  181. Sarkar M, Mookerjea S. Differential effect of inflammation and dexamethasone on dolichol and dolichol phosphate synthesis. Biochem Cell Biol. 1988;66:1265–1269
  182. Auerbach BJ, Parks JS. Lipoprotein abnormalities associated with lipopolysaccharide-induced lecithin: cholesterol acyltransferase and lipase deficiency. J Biol Chem. 1989;264:10264–10270
  183. Ettinger WH, Miller LD, Albers JJ, et al. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomolgus monkeys. J Lipid Res. 1990;31:1099–1107
  184. Sammalkorpi K, Valtonen V, Kerttula Y, et al. Changes in serum lipoprotein pattern induced by acute infections. Metabolism. 1988;37:859–865
  185. Ettinger WH, Varma VK, Sorci-Thomas M, et al. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb. 1994;14:8–13
  186. Schectman G, Kaul S, Mueller RA, et al. The effect of interferon on the metabolism of LDLs. Arterioscler Thromb. 1992;12:1053–1062
  187. Feingold KR, Spady DK, Pollock AS, et al. Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha-hydroxylase mRNA levels and activity. J Lipid Res. 1996;37:223–228
  188. Memon RA, Moser AH, Shigenaga JK, et al. In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response (potential role of hepatocyte nuclear factor-1). J Biol Chem. 2001;276:30118–30126
  189. Green RM, Beier D, Gollan JL. Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology. 1996;111:193–198
  190. Hartmann G, Cheung AK, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002;303:273–281
  191. Moseley RH, Wang W, Takeda H, et al. Effect of endotoxin on bile acid transport in rat liver: a potential model for sepsis-associated cholestasis. Am J Physiol. 1996;271:G137–G146
  192. Trauner M, Arrese M, Lee H, et al. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. J Clin Invest. 1998;101:2092–2100
  193. Vos TA, Hooiveld GJ, Koning H, et al. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology. 1998;28:1637–1644
  194. Tygstrup N, Bangert K, Ott P, et al. Messenger RNA profiles in liver injury and stress: a comparison of lethal and nonlethal rat models. Biochem Biophys Res Commun. 2002;290:518–525

 M.C.C. and J.G.F. contributed equally to this work.

 K.J.M. was supported by grant K08-DK07728, J.G.F. was supported by grants P30-ES02109 and R01-CA067529, and M.C.C. was supported by grants R01-DK073687 and R37-DK036588.

 The authors disclose no conflicts.

PII: S0016-5085(08)02187-2

doi: 10.1053/j.gastro.2008.12.031

Gastroenterology
Volume 136, Issue 2 , Pages 425-440 , February 2009

Article Tools

* Image Usage & Resolution